Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug safety hearing

This article was originally published in The Tan Sheet

Executive Summary

"To what extent do CDER's patient-focused communication tools provide useful information for people with low health literacy skills," is one question FDA's Center for Drug Evaluation & Research will address at a public hearing scheduled for Dec. 7-8. The center currently is seeking comment on six questions concerning CDER's ability to communicate drug safety information. The purpose of the hearing is to "obtain public input on CDER's current risk communication tools, identify stakeholders for collaboration and implementation of additional tools, and obtain greater understanding of the strengths and weaknesses of CDER's existing risk communication." Comments are due by Nov. 7...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS098708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel